ACLX
Arcellx, Inc.NASDAQHealthcare$114.77+0.02%ClosedMarket Cap: $6.71B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
16.05
P/S
301.03
EV/EBITDA
-33.97
DCF Value
$0.95
FCF Yield
-3.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-64.8%
Operating Margin
-1135.6%
Net Margin
-1027.3%
ROE
-55.4%
ROA
-37.9%
ROIC
-49.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.7M | 0.8% | $-63.7M | $-58.1M | $-1.00 | — |
| FY 2025 | $22.3M | 70.0% | $-253.1M | $-228.9M | $-4.07 | — |
| Q3 2025 | $4.9M | -609.0% | $-61.8M | $-55.8M | $-0.99 | — |
| Q2 2025 | $7.6M | 100.0% | $-58.7M | $-52.8M | $-0.94 | — |
| Q1 2025 | $8.1M | 100.0% | $-68.9M | $-62.3M | $-1.13 | — |
| Q4 2024 | $15.3M | 100.0% | $-53.2M | $-47.1M | $-0.88 | — |
| FY 2024 | $107.9M | 95.2% | $-137.6M | $-107.3M | $-2.00 | — |
| Q3 2024 | $26.0M | 100.0% | $-33.6M | $-25.9M | $-0.48 | — |
| Q2 2024 | $27.4M | 95.5% | $-35.0M | $-27.2M | $-0.51 | — |
| Q1 2024 | $39.3M | 97.9% | $-15.8M | $-7.2M | $-0.14 | — |
| Q4 2023 | $63.1M | 98.9% | $15.0M | $19.8M | $0.38 | — |
| FY 2023 | $110.3M | 100.0% | $-89.9M | $-70.7M | $-1.47 | — |